Skip to main content
. 2021 Dec 7;13(24):6158. doi: 10.3390/cancers13246158

Figure 7.

Figure 7

Morphological changes of EV and HER2 shRNA transduced organoids in PD-L1- huTGO/immune cell co-cultures as a result of different treatment conditions. huTGO spheroid/immune cell co-cultures were established using EV and HER2 shRNA knockdown organoids in AggreWells. Changes in the area of huTGOs were measured after 48 h of vehicle (Control) treatment in co-cultures with CTLs (a,b), Nivolumab (Condition 2, c,d) or Mubritinib (Condition 3, e,f); in co-cultures with CTLs, Nivolumab and PMN-MDSCs (Condition 4, g,h), or CTLs, Mubritinib and PMN-MDSCs (Condition 5, i,j); or in a combinatorial treatment of Nivolumab and Cabozantinib (Condition 6, k,l) or Mubritinib and Cabozantinib (Condition 7, m,n) in co-cultures with CTLs and PMN-MDSCs. * p < 0.05 to p < 0.0001 compared to 0 h time point for each condition.